Who Paid My Doc
Mark Brzezienski
Plastic and Reconstructive Surgery Chattanooga, TN Medical Doctor
NPI 1487621926 CMS profile 111949
979 E 3Rd St, Suite C920, Chattanooga, TN 37403
General payments
$31,530
Research payments
$8,746
Ownership & investment interest
$0
Research they led as principal investigator
$391,661
Through program year 2025, Mark Brzezienski of Chattanooga, TN is reported in the CMS Open Payments database as having received $31,530 across 73 general payments and $8,746 in research payments paid to them. Separately, studies naming them as principal investigator received $391,661 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,092 | 18 | |
| 2025 | Research | $2,510 | 2 | |
| 2024 | General | $674 | 2 | |
| 2024 | Research | $1,742 | 2 | |
| 2023 | General | $216 | 8 | |
| 2022 | General | $1,692 | 11 | |
| 2022 | Research | $2,632 | 4 | |
| 2021 | General | $14,163 | 12 | |
| 2021 | Research | $1,011 | 2 | |
| 2020 | General | $980 | 4 | |
| 2020 | Research | $851 | 1 | |
| 2019 | General | $8,714 | 18 |
Beside peers
- Mark Brzezienski
- Plastic and Reconstructive Surgery median
- Middle half of Plastic and Reconstructive Surgery
- National median
In program year 2025, general payments to Mark Brzezienski were reported at $5,092. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.
Show as a table
| Year | Mark Brzezienski | Plastic and Reconstructive Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,714 | $335 | $121–$1,264 | $163 |
| 2020 | $980 | $162 | $57–$417 | $114 |
| 2021 | $14,163 | $245 | $89–$735 | $132 |
| 2022 | $1,692 | $325 | $120–$932 | $149 |
| 2023 | $216 | $343 | $129–$999 | $160 |
| 2024 | $674 | $390 | $141–$1,085 | $164 |
| 2025 | $5,092 | $442 | $150–$1,242 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
249
Drug cost
$836
Branded share of claims
35.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cephalexin | Generic | 78 | $366 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 45 | $105 | |
| Gabapentin | Generic | 17 | $95 | |
| Hydroxyzine Hcl | Generic | 39 | $88 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 32 | $87 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 12 | $62 | |
| Tramadol Hcl | Generic | 26 | $35 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,399 Part D prescribers listed as Hand Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 53 billing codesPaid by Medicare
$41,312
Medicare patients
98
Services billed
242
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Arthritis | 64% | |
| Cancer | 40% | |
| Ischemic heart disease | 31% | |
| Diabetes | 28% | |
| Depression | 21% | |
| Chronic kidney disease | 17% | |
| Osteoporosis | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
84 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Plastic and Reconstructive Surgery in Tennessee
William Hickerson
Plastic and Reconstructive Surgery · Memphis, TN
Daniel Hatef
Plastic and Reconstructive Surgery · Nashville, TN
Earl Lett
Plastic and Reconstructive Surgery · Mount Juliet, TN
Robert Wallace
Plastic and Reconstructive Surgery · Memphis, TN
Lois Wagstrom
Plastic and Reconstructive Surgery · Nashville, TN
Jordi Puente Espel
Plastic and Reconstructive Surgery · Nashville, TN
Related records
Plastic and Reconstructive Surgery in Tennessee
Practitioners in the same specialty and state, ranked by reported value.
All Plastic and Reconstructive Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Tennessee
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.